Overview Statistic: PDF-Downloads (blue) and Frontdoor-Views (gray)

Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2

  • Measurable levels of immunoglobulin G antibodies develop after infections with and vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These antibody levels are dynamic: due to waning, antibody levels will drop over time. During the COVID-19 pandemic, multiple models predicting infection dynamics were used by policymakers to support the planning of public health policies. Explicitly integrating antibody and waning effects into the models is crucial for reliable calculations of individual infection risk. However, only few approaches have been suggested that explicitly treat these effects. This paper presents a methodology that explicitly models antibody levels and the resulting protection against infection for individuals within an agent-based model. The model was developed in response to the complexity of different immunization sequences and types and is based on neutralization titer studies. This approach allows complex population studies with explicit antibody and waning effects. We demonstrate the usefulness of our model in two use cases.

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics - number of accesses to the document
Author:Sebastian Müller, Sydney Paltra, Jakob Rehmann, Kai Nagel, Tim ConradORCiD
Document Type:Article
Parent Title (English):iScience
Year of first publication:2023
Accept ✔
Diese Webseite verwendet technisch erforderliche Session-Cookies. Durch die weitere Nutzung der Webseite stimmen Sie diesem zu. Unsere Datenschutzerklärung finden Sie hier.